Blue Cross Blue Shield MA anti-obesity meds Coverage Update | OpenPayer
ModifiedBlue Cross Blue Shield - MassachusettsPolicy 572
Pharmacologic management of obesity (anti-obesity medications)
Defines medical necessity, prior authorization, and continuation criteria for specific anti-obesity medications (including Contrave, Imcivree, Saxenda, Wegovy, Zepbound) for BCBSMA commercial members and describes pharmacy operations and step-therapy requirements.
Policy Summary
PayerBlue Cross Blue Shield - Massachusetts
PolicyPharmacologic management of obesity (anti-obesity medications)
Zepbound (tirzepatide) added to the policy as a covered medication for obesity with specific initial and continuation criteria.
Wegovy's cardiovascular (MACE) indication and related criteria were added/updated including age, BMI, established CVD, and SOC requirements.
Significant weight loss thresholds for continuation differ by agent (e.g., Saxenda 4% at 16 weeks; Wegovy 5% at 16 weeks; Zepbound 5% at 20 weeks).
6 monthsrequired prior comprehensive weight loss trial duration
≥5%weight loss threshold for renewal for multiple drugs
6 months
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
Contrave (naltrexone-bupropion) covered when ALL of the following are met:
Age: Member is 18 years of age or older
Prior comprehensive program: Physician attestation/documentation of at least a 6-month trial of a comprehensive weight loss plan (reduced-calorie diet, increased physical activity, behavioral modifications) prior to initiation6 months
Adjunct use: Physician attestation/documentation that medication will be used as an adjunct to a comprehensive weight management plan
BMI criteria: Initial BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes)BMI thresholds
Continuation Therapy - Contrave
Continuation criteria for Contrave — ALL of the following:
Response: Documented weight loss of at least 5% of baseline body weight after initiation (first 12 weeks) OR maintenance of at least 5% below baseline>=5%
Adherence/tolerability: Documentation that patient is adherent and tolerating recommended maintenance dose for at least 3 consecutive months3 months
Initial and Renewal Therapy - Imcivree
Imcivree (setmelanotide) covered when ALL of the following are met:
Diagnosis: Patient has a diagnosis of obesity (adults: BMI ≥30 kg/m2; pediatric patients ≥2 years) appropriate to agent labelingBMI thresholds
Genetic confirmation: Obesity due to a homozygous or presumed compound heterozygous variant in PCSK1, POMC, or LEPR confirmed by genetic testing with variants interpreted as pathogenic, likely pathogenic, or VUS OR documentation of Bardet-Biedl syndromegenetic test
Documentation of genetic testing results required
Continuation response for renewal: First renewal: at least 5% reduction in baseline body weight OR 5% reduction in baseline BMI for growing patients; Subsequent renewal: maintenance of at least 5% reduction in body weight or BMI>=5%
Initial Therapy - Saxenda
Saxenda (liraglutide) covered when ALL of the following are met:
Age/weight criteria: Pediatrics: age 12–17 with weight >60 kg and required baseline BMI, baseline weight, and BMI% documentation OR Adults: initial BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one weight-related comorbid conditionage and BMI thresholds
Pediatric documentation required
Prior comprehensive program: Physician attestation/documentation of engagement in a 6-month comprehensive weight loss plan prior to initiation6 months
Adjunct use: Physician attestation/documentation that medication will be used as an adjunct to a comprehensive weight management plan
Saxenda — Initial Approval
Covered when ALL of the following are met
Saxenda initial criteria: Patient is either age 12–17 with documentation of body weight > 60 kg and baseline BMI/baseline weight/BMI percentile, OR an adult with BMI ≥30 kg/m2, OR an adult with BMI ≥27 kg/m2 plus ≥1 weight-related comorbidity; AND physician attestation/documentation of a 6-month trial of a comprehensive weight loss plan prior to initiation; AND physician attestation that medication will be used as an adjunct to a comprehensive weight management plan.see node text
Pediatric documentation required
Saxenda — Continuation
May renew when ALL of the following are met
Saxenda continuation: Documented significant weight loss by meeting ONE condition: continued weight loss OR ≥4% of baseline body weight after initiation within first 16 weeks OR maintaining plateau weight achieved with diet/exercise; AND documentation of adherence and tolerability to recommended maintenance dose for at least 3 consecutive months.≥4% at 16 weeks option
Adherence and tolerability required
Wegovy — Initial Approval (weight management)
Covered when ALL of the following are met
Wegovy initial criteria: Patient is 12–17 with initial BMI ≥95th percentile for age/gender (include baseline BMI, weight, BMI%), OR an adult with BMI ≥30 kg/m2, OR an adult with BMI ≥27 kg/m2 plus ≥1 weight-related comorbidity; AND physician attestation/documentation of a 6-month trial of a comprehensive weight loss plan prior to initiation; AND documentation that patient will continue comprehensive weight management plan while using medication.pediatric 95th percentile or adult BMI thresholds
Pediatric documentation required
Wegovy — Continuation (weight management and MACE)
May renew when ALL of the following are met
Wegovy continuation (weight): Patient is on 2.4 mg or 1.7 mg dose; AND documented significant weight loss by meeting ONE condition: continued weight loss OR ≥5% of baseline body weight after initiation within first 16 weeks OR maintaining plateau weight; AND documentation of adherence/tolerability to recommended maintenance dose for at least 3 consecutive months; AND documentation patient continues comprehensive weight management plan.≥5% at 16 weeks option
Dose-specific requirement
Wegovy continuation (MACE): Individual continues to meet initial approval criteria for MACE indication; AND adherent to therapy with claims evidence >80% fill rate; AND individual has not developed Type 2 Diabetes or NYHA class IV heart failure; AND member remains on Standard of Care therapies for CVD.>80% fill rate for adherence
Separate renewal pathway for MACE indication
Zepbound — Initial Approval
Covered when ALL of the following are met
Zepbound initial criteria: Member is ≥18 years old; AND physician attestation/documentation that member has engaged in at least a 6-month trial of a comprehensive weight loss plan prior to initiation; AND physician attestation that medication will be used as an adjunct to comprehensive weight management; AND initial BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with ≥1 weight-related comorbidity.adult age and BMI thresholds
6-month prior lifestyle intervention required
Zepbound — Continuation
May renew when ALL of the following are met
Zepbound continuation: Patient is on 5 mg, 10 mg, or 15 mg dose; AND documented significant weight loss by meeting ONE condition: continued weight loss OR ≥5% of baseline body weight after initiation within first 20 weeks OR maintaining plateau weight; AND documentation of adherence and tolerability to recommended maintenance dose for at least 3 consecutive months; AND documentation that patient continues comprehensive weight management plan.≥5% at 20 weeks option
Dose-specified continuation
Medications addressed by this policy are covered only for the indications and patient populations specifically listed. We do not cover these medications for conditions not listed in this policy unless another Blue Cross Blue Shield MA medical policy explicitly authorizes coverage for that condition. Providers must submit supporting clinical documentation (chart notes, labs, baseline BMI/weight, pediatric BMI percentile where applicable) to demonstrate that the member meets all approval criteria.
All GLP-1 and GIP agents included in this policy (current and future FDA approvals for weight loss) are limited to a 1-month supply (28–30 days) per fill, are excluded from mail-order pharmacy, and refills will generally be allowed only after at least 75% of days supplied have been exhausted. Requests based solely on manufacturer samples will not meet continuing coverage criteria and additional clinical information is required to establish medical necessity.
For Wegovy when requested for the MACE (major adverse cardiovascular events) indication, patients with NYHA class IV heart failure are excluded and therefore do not meet the MACE-specific approval or continuation criteria. Providers must confirm the patient is not NYHA class IV as part of the documentation for MACE use.
Requests based exclusively on the use of samples will not meet criteria for continuing coverage. When samples have been used, the prescriber must submit additional clinical documentation that demonstrates medical necessity (for example, baseline BMI/weight, prior comprehensive weight-management efforts, and objective evidence of treatment response) to support approval or renewal.
Belviq (lorcaserin) and BELVIQ XR were removed from coverage following the FDA withdrawal of these products. This historical change is noted to clarify that previously available coverage for those agents no longer applies.
Coding, BMI Thresholds, and Weight-Loss Metrics
Formulary medications affectedmixed
Contrave
naltrexone bupropion — formulary status PA, QCD
Imcivree
setmelanotide — formulary status PA, QCD
Saxenda
liraglutide — formulary status PA, QCD
Wegovy
semaglutide — formulary status PA, QCD
Zepbound
tirzepatide — formulary status PA, QCD
BMI — Adult and pediatric BMI thresholds and special pediatric weight criteria
Adult BMI thresholdsInitial BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one weight‑related comorbidity (e.g., hypertension, dyslipidemia, type 2 diabetes)
Pediatric Saxenda criteria (age/weight)Age 12–17 with body weight >60 kg; must include baseline BMI, baseline weight, and BMI percentile documentation
Pediatric Imcivree age thresholdPediatric patients ≥2 years eligible for Imcivree where indicated (documented per agent labeling)
Weight loss thresholds — Agent-specific thresholds for continuation (Saxenda, Wegovy, Zepbound)
Saxenda continuation threshold≥4% of baseline body weight after initiation within the first 16 weeks (option for documented significant weight loss)
Prior Authorization, Documentation, and Operational Requirements
Prior Authorization
Prior Authorization Required
Prior authorization required through Pharmacy Operations for affected agents. Failure to obtain prior authorization may result in denial or member out-of-pocket costs.
Policy applies to BCBSMA Commercial formulary members (see formulary/step status)
Documentation Required
Initial authorization requirements
Initial authorization requires documentation of eligibility and prior conservative therapy. Provider must submit clinical records (chart notes, labs, weight/BMI) and attestations to demonstrate criteria are met.
Age criteria (e.g., Contrave: ≥18 years) and agent-specific BMI thresholds (initial BMI ≥30 kg/m2 or ≥27 kg/m2 with weight-related comorbidity)
Definitions and Diagnostic Criteria
Comprehensive weight loss plan — Definition and components (6-month trial: diet, activity, behavioral modification)
DefinitionA documented 6-month trial including a reduced‑calorie diet, increased physical activity, and behavioral modifications prior to initiation of pharmacotherapy
Provider documentationPhysician attestation or chart documentation that the member engaged in the 6‑month comprehensive weight loss plan
Role of medicationMedication must be used as an adjunct to the comprehensive weight management plan (attestation required)
Genetic/syndromic obesity for Imcivree — Definition of genetic causes and eligible gene variants/syndromes
Eligible genetic causesHomozygous or presumed compound heterozygous variants in PCSK1, POMC, or LEPR genes
Syndromic obesity eligibility
Background
Obesity pharmacotherapy is provided as an adjunct to a comprehensive weight management program and is not intended as sole therapy. Coverage under this policy applies when medication is used in combination with a documented comprehensive weight loss plan — typically a 6-month trial of a reduced-calorie diet, increased physical activity, and behavioral modification — and when the prescriber attests that the drug will be used as an adjunct to ongoing lifestyle management.
Agents addressed include centrally acting agents (e.g., Contrave), medications for genetic/syndromic obesity (Imcivree/setmelanotide), and GLP-1/GIP class agents (e.g., Saxenda, Wegovy, Zepbound). Prior authorization is required and continuation approvals depend on agent-specific response thresholds and documentation of adherence and tolerability.
Policy Revision History
2024-?additionLatest
Zepbound (tirzepatide) added to policy as a covered medication for obesity with specified initial and continuation criteria (including 6-month prior lifestyle intervention and ≥5% weight-loss threshold at 20 weeks).
2024-?revision
Wegovy cardiovascular (MACE) indication criteria were added/updated to include age and BMI thresholds, requirement for standard-of-care CVD therapies, and an adherence metric (>80% fill rate) for continuation approvals.
2024-?
Policy Summary
PayerBlue Cross Blue Shield - Massachusetts
PolicyPharmacologic management of obesity (anti-obesity medications)
Documentation of adherence and continued comprehensive weight management plan required
Wegovy continuation threshold (weight management)
≥5% of baseline body weight after initiation within the first 16 weeks (or continued weight loss/maintenance of plateau)
Zepbound continuation threshold≥5% of baseline body weight after initiation within the first 20 weeks (or continued weight loss/maintenance of plateau)
Wegovy MACE age and BMI — Age and BMI criteria for Wegovy MACE indication
Age requirement for Wegovy MACE indicationPatient age ≥45 years
BMI requirement for Wegovy MACE indicationBMI ≥27 kg/m2
Other MACE-specific exclusionsPatient must not have developed Type 2 diabetes or NYHA class IV heart failure and must remain on Standard of Care CVD therapies
Physician attestation or documentation of a prior 6-month trial of a comprehensive weight loss plan (reduced-calorie diet, increased physical activity, behavioral modifications) before initiation
Attestation that medication will be used adjunctively with a comprehensive weight management plan
Supporting documentation must be submitted (chart notes, labs, baseline weight/BMI or pediatric BMI percentile)
Documentation Required
Continuation / renewal requirements
Continuation/renewal approvals require evidence of clinical benefit, adherence, and tolerability. Specific agent rules apply (see Imcivree and GLP-1/GIP details).
First renewal for obesity treatment: 4 months; subsequent renewals: 12 months (or as otherwise indicated)
At renewal submit documentation of agent-specific percent weight loss within the required timeframe, evidence of adherence to therapy, and tolerability/absence of prohibitive adverse effects
Requests based exclusively on samples will not meet continuing coverage criteria — additional clinical information must be provided
Step Therapy
Step therapy / formulary exceptions
Step therapy and formulary exceptions: many agents are PA and QCD; non-formulary requests may require prior failure or contraindication to formulary alternatives and may require individual consideration.
For non-covered medications, member must have previous treatment failure with, or contraindication to, at least two covered formulary alternatives when available
Formulary status for affected agents (commercial) = PA, QCD (e.g., Contrave, Imcivree, Saxenda, Wegovy, Zepbound)
Providers may request formulary exceptions or individual consideration if criteria cannot be met
Note
Use of claims to verify step therapy
Claims may be used to document prior use of formulary alternatives to satisfy step therapy requirements when clinical notes are unavailable.
Pharmacy claims can demonstrate prior utilization of formulary agents to support exception requests or meet step therapy evidence
Documentation Required
Required documentation
Required documentation must be submitted with initial and renewal requests to support medical necessity.
Physician attestations: prior 6-month comprehensive weight loss plan and intent to use medication adjunctively
For continuity requests include prior authorization start date, dates of therapy, and objective measures of response (weight change, percent weight loss)
Documentation Required
Genetic testing documentation (Imcivree)
Genetic testing documentation is required for Imcivree (setmelanotide). Providers must submit confirmatory genetic test results and interpretation.
Documentation confirming homozygous or presumed compound heterozygous pathogenic, likely pathogenic, or VUS in POMC, PCSK1, or LEPR genes
Clinical documentation of monogenic or syndromic obesity due to Bardet-Biedl syndrome when applicable
Documentation Required
Prior behavioral therapy documentation
Prior behavioral therapy documentation is required prior to initiation for most agents.
Documentation or physician attestation of at least a 6-month trial of a comprehensive weight loss plan (reduced-calorie diet, increased physical activity, behavioral modifications) before starting therapy
Documentation Required
Continuation documentation
Continuation documentation at renewal must include objective response, adherence, and tolerability details.
Percent weight loss within the specified timeframe for the agent, with dates and baseline comparator
Documentation of adherence to prescribed regimen and tolerability (adverse effects, dose changes)
Exclusion of requests based solely on sample use without supporting clinical data
Billing Rule
Refill and supply limits for GLP-1/GIP
GLP‑1/GIP agents for weight loss are limited operationally to a 1-month supply per fill and excluded from mail order; refills limited to 75% of days used before refill.
Supply limit: 28–30 days per fill; excluded from mail order pharmacy benefit
Refill restriction: 75% of days of the current supply must be exhausted before a refill will be allowed
For Wegovy use with cardiovascular MACE outcomes, absence of documentation of standard-of-care cardiovascular therapies or exclusion criteria (e.g., NYHA class IV) may result in denial.
Submit evidence of standard-of-care cardiovascular therapies when MACE-related indications are claimed
Document absence of advanced heart failure (NYHA class IV) if applicable to the request
Documentation of Bardet‑Biedl syndrome as an acceptable syndromic cause
Genetic test interpretation requiredVariants must be interpreted as pathogenic, likely pathogenic, or variant of uncertain significance (VUS) on genetic testing documentation
Established cardiovascular disease (CVD) — Definition examples (MI, stroke, PAD with ABI <0.85, etc.)
Myocardial infarction (MI)Prior myocardial infarction is considered established cardiovascular disease
Prior strokeHistory of prior stroke meets the definition of established CVD
Peripheral artery disease (PAD) with ABI criterionCurrent intermittent claudication with ankle‑brachial index (ABI) <0.85 or symptomatic PAD evidenced by prior peripheral arterial revascularization or prior amputation due to ASCVD
Adherence — Definition for Wegovy MACE continuation (>80% fill rate) and general adherence documentation expectations
Wegovy MACE adherence metric>80% fill rate evidenced in claims records for continuation of Wegovy for MACE indication
General adherence expectationDocumentation that patient is adherent and tolerating recommended maintenance dose for at least 3 consecutive months for continuation of therapy
Evidence sourcesAdherence may be demonstrated using pharmacy claims records and provider documentation submitted with prior authorization renewal
clarification
Continuation/renewal requirements across agents were clarified to specify agent-specific weight-loss thresholds (e.g., Saxenda ≥4% at 16 weeks; Wegovy ≥5% at 16 weeks; Zepbound ≥5% at 20 weeks) and documentation of adherence/tolerability.
2024-?operational
A 30-day supply limit and refill/supply restrictions were applied to GLP-1/GIP agents (GLP-1/GIP prescriptions limited to 1-month supply per fill and excluded from mail order).